Scancell Holdings plc (AIM: SCLP), a clinical stage biopharmaceutical company, reported on Tuesday that it has dosed the first patient with iSCIB1+ and doublet checkpoint inhibitor therapy, consisting of ipilimumab (Yervoy) plus nivolumab (Opdivo) in the SCOPE trial, marking a significant milestone in cancer immunotherapy.
iSCIB1+ is an enhanced version of SCIB1 developed to broaden effectiveness beyond specific tissue types. With similarities to SCIB1, iSCIB1+ is anticipated to yield exceptional results, targeting a broader range of melanoma patients. The trial's early data is expected by Q4 2024.
These advancements pave the way for a Phase 2/3 seamless adaptive registration programme targeting unresectable melanoma, a market estimated at USD1.5bn annually.
Scancell utilises innovative platforms like Moditope, ImmunoBody, GlyMab and AvidiMab to develop novel medicines addressing significant unmet needs in cancer and infectious diseases. Its unique approach leverages adaptive immune responses to induce immune reactions or redirect immune cells, targeting modifications of proteins and lipids for enhanced therapeutic efficacy.
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
Vistagen secures US patent for AV-101 in neuropathic pain treatment
Thermo Fisher Scientific launches international registry for adolescent alopecia areata
hVIVO successfully completes RSV antiviral trial for Shionogi
Valneva secures UK approval for world's first chikungunya vaccine
Alys Pharmaceuticals' IND for ALY-101 approved in US and Canada
NeuroTherapia's Phase 2 Alzheimer's disease trial receives European regulatory approval
NFL Biosciences confirms superior safety profile of NFL-101 in new toxicity study
Avirmax Biopharma completes first cohort of Wet AMD clinical trial
PhaseV collaborates with Alimentiv to address challenges in GI clinical trials
HOPE Therapeutics and NRx Pharmaceuticals select BTIG as financial advisor
Helix unveils clinico-genomic dataset of over 15,000 patients treated with GLP-1 agonists
Roquefort Therapeutics sells Lyramid for USD10.8m equity deal with Pleiades Pharma